Holen Sie sich die Stockscreener-App
28.29
1.84%
-0.53
Handel nachbörslich:
28.29
Schlusskurs vom Vortag:
$28.82
Offen:
$28.7
24-Stunden-Volumen:
499.20K
Relative Volume:
0.70
Marktkapitalisierung:
$1.43B
Einnahmen:
$534.53M
Nettoeinkommen (Verlust:
$-11.45M
KGV:
-117.34
EPS:
-0.2411
Netto-Cashflow:
$48.28M
1W Leistung:
+0.60%
1M Leistung:
+2.39%
6M Leistung:
-21.79%
1J Leistung:
-13.78%
1-Tages-Spanne:
$28.01
$28.95
1-Wochen-Bereich:
$28.01
$29.45
52-Wochen-Spanne:
$25.52
$43.18
Atricure Inc Stock (ATRC) Company Profile
Firmenname
Atricure Inc
Sektor
Telefon
513-755-4100
Adresse
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
28.29 | 1.46B | 534.53M | -11.45M | 48.28M | -0.2411 |
ISRG
Intuitive Surgical Inc
|
438.10 | 155.76B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.63 | 40.30B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.78 | 33.13B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.01 | 31.37B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.05 | 30.31B | 5.54B | 1.52B | 1.74B | 10.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2026-02-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-17 | Fortgesetzt | JP Morgan | Overweight |
| 2024-04-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-23 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-09-29 | Eingeleitet | UBS | Buy |
| 2021-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-12-18 | Bestätigt | Needham | Buy |
| 2020-11-06 | Bestätigt | Needham | Buy |
| 2020-04-07 | Eingeleitet | Oppenheimer | Outperform |
| 2020-02-06 | Eingeleitet | BTIG Research | Buy |
| 2020-01-24 | Bestätigt | Needham | Buy |
| 2019-08-13 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | Eingeleitet | JP Morgan | Overweight |
| 2018-10-04 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-08-02 | Bestätigt | Stifel | Buy |
| 2018-06-18 | Bestätigt | Needham | Buy |
| 2018-04-27 | Bestätigt | Needham | Buy |
| 2018-01-16 | Bestätigt | Needham | Buy |
| 2017-11-02 | Bestätigt | Needham | Buy |
| 2017-07-28 | Bestätigt | Needham | Buy |
| 2017-05-30 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-06-30 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2015-10-28 | Bestätigt | Needham | Buy |
| 2015-10-06 | Bestätigt | Canaccord Genuity | Buy |
| 2015-10-06 | Bestätigt | Needham | Buy |
Alle ansehen
Atricure Inc Aktie (ATRC) Neueste Nachrichten
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC) - GuruFocus
(ATRC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AtriCure director Karen Prange sells $85,950 in company stock By Investing.com - Investing.com Canada
AtriCure director Karen Prange sells $85,950 in company stock - Investing.com
AtriCure (ATRC) director Prange sells 3,000 shares, keeps 26,373 - Stock Titan
Director Karen Prange granted 6,144 AtriCure (ATRC) shares - Stock Titan
AtriCure (ATRC) director Deborah Telman awarded 6,144 restricted shares - Stock Titan
AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award - Stock Titan
Director Nachman Shlomo receives 6,144 AtriCure (ATRC) restricted shares - Stock Titan
Director Kristine Johnson receives 6,144-share grant at AtriCure (ATRC) - Stock Titan
AtriCure (ATRC) director Regina Groves receives 6,144-share restricted stock grant - Stock Titan
AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant - Stock Titan
Director at AtriCure (ATRC) receives 6,144-share restricted stock grant - Stock Titan
[144] AtriCure, Inc. SEC Filing - Stock Titan
AtriCure Shareholders Approve Expanded Equity and Governance Plans - TipRanks
AtriCure (ATRC) stockholders back equity plan share increases and director slate - Stock Titan
AtriCure conference: New devices, EnCompass drive 2026 growth outlook - MSN
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $28.13 - Stock Titan
AtriCure Inc Annual Shareholders Meeting Transcript - GuruFocus
Loss-Making AtriCure, Inc. (NASDAQ:ATRC) Set To Breakeven - Moomoo
ATRC (NASDAQ: ATRC) Form 144 shows 5,000-share sale and planned award disposals - Stock Titan
Wellington Management holds 3,382,555 ATRC shares (6.79%) — institutional stake - Stock Titan
AtriCure Inc (ATRC) Shares Surge 5.8% -- What GF Score of 79 Tel - GuruFocus
AtriCure stock (US04963C1099): Q1 revenue jumps 14% to $141M amid return to profit - AD HOC NEWS
AtriCure, Inc.Common Stock (NQ: ATRC - FinancialContent
AtriCure (ATRC) Is Down 5.1% After Q1 Return To Profitability And Higher Revenue Guidance – What's Changed - simplywall.st
TradingKey - TradingKey
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook - sharewise.com
ATRC: Innovation, clinical trials, and new launches drive growth and reinforce market leadership - TradingView
Transcript : AtriCure, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10 - marketscreener.com
Responsive Playbooks and the ATRC Inflection - Stock Traders Daily
AtriCure, Inc. $ATRC Shares Purchased by Vanguard Group Inc. - MarketBeat
Number of shareholders of AtriCure, Inc. – NASDAQ:ATRC - TradingView
Number of shareholders of AtriCure, Inc. – DUS:A5I - TradingView
ATRC Stock Price, Quote & Chart | ATRICURE INC (NASDAQ:ATRC) - ChartMill
Assessing AtriCure (ATRC) Valuation After A Prolonged Share Price Decline - Yahoo Finance
AtriCure Inc stock hits 52-week low at 26.62 USD By Investing.com - Investing.com Australia
AtriCure, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ATRC) 2026-05-08 - Seeking Alpha
AtriCure Inc stock hits 52-week low at 26.62 USD - Investing.com
AtriCure : Investor Presentation Q1 2026 vF - marketscreener.com
AtriCure Q1 Loss Narrows, Revenue Increases; 2026 Guidance Maintained - Moomoo
AtriCure, Inc. (NASDAQ:ATRC) Q1 2026 Earnings Call Transcript - Insider Monkey
AtriCure Earnings Call Highlights Profitable Growth Pivot - TipRanks
AtriCure Price Target Raised to $55.00/Share From $53.00 by Canaccord Genuity - Moomoo
AtriCure, Inc. 1Q 2026: Revenue $141.25M, EPS $0— 10-Q Summary - TradingView
AtriCure (NASDAQ: ATRC) posts Q1 2026 growth, swings to profit - Stock Titan
Stifel Maintains AtriCure(ATRC.US) With Buy Rating, Maintains Target Price $50 - Moomoo
AtriCure reiterates 2026 revenue $600M-$610M as BoxX-NoAF enrollment targets year-end completion - MSN
AtriCure (ATRC) reports break-even earnings for Q1 - MSN
AtriCure (ATRC) Q1 2026 Earnings Transcript - The Globe and Mail
Finanzdaten der Atricure Inc-Aktie (ATRC)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.79%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):